Drug intelligence / Profile preview

Photosens

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous, Intravesical

Overview

Photosens is a light-sensitizing agent utilized in photodynamic therapy (PDT). Upon activation by specific wavelengths of light, Photosens enters an excited state and subsequently generates reactive oxygen species (ROS) and free radicals. These highly reactive molecules cause direct cellular damage, leading to cell death. This mechanism of action makes Photosens effective in the treatment of various conditions, including precancerous lesions and early-stage cancers.

Brand names: Photosens

Beyond the preview

Go deeper on Photosens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Photosens.

Explore the full profile